There were, naturally, several factors at play. It wasn’t just luck, although a certain amount of serendipity is always welcome in the stock market. It’s a bit like making a decent cup of tea: you need the right ingredients, a bit of skill, and a healthy dose of not messing it up. And AbbVie, it seems, didn’t mess it up.
The CORP-DEPO people did a survey, and nine out of ten investors said they’re sticking with AI stocks, or even adding more. Not a lot of panic, apparently. Which is… something. It’s like watching people rearrange the deck chairs on the Titanic, only the iceberg is made of code and the band is playing algorithms. So it goes.
The official pronouncements, of course, are couched in the dry language of SEC filings, dated January 28, 2026, detailing a reduction in position. But let us not be deceived by such sterile accounting. The true story, as always, lies beneath the surface, swirling in the murky depths of market sentiment. The quarter-end value, diminished by $13.64 million, is not merely a number; it is a symptom, a feverish flush upon the face of a troubled enterprise. A most peculiar fever, I might add, one that smells faintly of damp wool and forgotten promises.
Come January 28th, 2026, they filed a notice with the SEC – a fancy way of sayin’ they told the government what they’d been up to. Seems they sold off 373,236 shares of JD.com during the last quarter. That’s a goodly sum, and it shrunk the value of their holdin’s in that company by $14.03 million – a loss accounted for by both the sellin’ and the stock itself takin’ a tumble. They still got some – 155,104 shares, worth around $4.45 million – but they’re clearly lighten’ their load.
Stonebridge, see, they filed a notice with the government folk—the Securities and Exchange Commission, a body dedicated to keeping things…complicated—reportin’ the sale of most of their holdings in this AI-focused fund. The value of that AIQ position shrunk by a good $15.21 million, not just from the sellin’, mind you, but also from the market doin’ what it always does: wiggling and wobblin’ like a newborn calf.
Lantz Financial, a firm dedicated to the art of arranging money in a manner that hopefully results in more money, increased its holdings in BSCR. This isn’t, strictly speaking, news. People buy things. It’s what they do. However, the increase amounted to approximately $5.34 million, based on the average quarterly closing price. This sum, incidentally, is roughly equivalent to the annual GDP of a small, moderately prosperous island nation… or the cost of a really good cup of coffee if you factor in inflation over the next century. (The calculations are, admittedly, a little fuzzy.) The quarter-end value of their position increased by the same amount, a fact which, while mathematically accurate, doesn’t necessarily imply anything profound about the nature of reality.)
Robinhood’s growth, it must be said, has been a thing of peculiar beauty. It’s a vine that sprouted from barren soil, nurtured by the impatience of a new generation. While others measured risk in spreadsheets and quarterly reports, Robinhood offered a different currency: access. In the last quarter, ending September 30th, 2025, the company doubled its revenues, a surge that felt less like calculated strategy and more like a prophecy fulfilled. Profits, too, blossomed, tripling from a modest $150 million to a considerable $556 million. These numbers, however, are merely the surface of a deeper current, a restlessness that suggests both opportunity and peril. The margins are improving, yes, but even the most vibrant blossoms eventually wither.
The stock, Teladoc Health, has already known its share of headwinds, a rather ungainly vessel tossed about by the currents of the market. It leaves one to wonder if this change in Medicare policy will deliver yet another blow. Let us examine the particulars, not with the fervor of a gambler, but with the detached curiosity of one observing a slow, unfolding drama.
The fourth quarter figures, you see, were remarkably robust. Revenue climbed a healthy 17.6% year-on-year to $12.1 billion, a sum that would make most chaps sit up and take notice. Earnings per share perked up by a respectable 30.2% to $0.56, and free cash flow positively galloped ahead by 35.8% to $1.9 billion. Netflix remains, undeniably, the king of the streaming jungle, boasting over 325 million paid subscribers – a truly staggering number when you think about it. They’re launching a good deal of fresh content, and that, naturally, is attracting more of the paying public. A decidedly promising state of affairs, wouldn’t you agree?
This represents a new allocation for Generali, comprising 1.29% of their reportable Assets Under Management (AUM). AUM, for the uninitiated, is a term that sounds far more impressive than it actually is. It essentially means the total value of all the things they’re looking after. Like a very large, slightly anxious sheepdog. Their top holdings, for those keeping score at home, are as follows: